She has built a reputation as one of the most powerful and influential lawyers in the world but Pfizer has confirmed that its high-profile general counsel and executive leadership member Amy Schulman is to leave the pharma giant just weeks before the in-house lawyer was due to take up a new post.
Schulman had joined Pfizer in 2008 from her position as co-head of mass tort and class actions at DLA Piper. The star litigator, who was reportedly responsible for a $60m book of business, was an equally high-profile general counsel going on to pioneer the Pfizer Legal Alliance, a radical attempt to usher in annually fixed fees for advisers that entirely ditched the billable hour.
